Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Global analysis of L1-transcriptomes identified IGFBP-2 as a target of ezrin and NF-κB signaling that promotes colon cancer progression

Oncogene volume 32, pages 3220–3230 (2013)Cite this article

Subjects

Abstract

L1, a neuronal cell adhesion receptor of the immunoglobulin-like protein family is expressed in invading colorectal cancer (CRC) cells as a target gene of Wnt/β-catenin signaling. Overexpression of L1 in CRC cells enhances cell motility and proliferation, and confers liver metastasis. We recently identified ezrin and the IκB-NF-κB pathway as essential for the biological properties conferred by L1 in CRC cells. Here, we studied the underlying molecular mechanisms and found that L1 enhances ezrin phosphorylation, via Rho-associated protein kinase (ROCK), and is required for L1–ezrin co-localization at the juxtamembrane domain and for enhancing cell motility. Global transcriptomes from L1-expressing CRC cells were compared with transcriptomes from the same cells expressing small hairpin RNA (shRNA) to ezrin. Among the genes whose expression was elevated by L1 and ezrin we identified insulin-like growth factor-binding protein 2 (IGFBP-2) and showed that its increased expression is mediated by an NF-κB-mediated transactivation of the IGFBP-2 gene promoter. Expression of a constitutively activated mutant ezrin (Ezrin567D) could also increase IGFBP-2 levels in CRC cells. Overexpression of IGFBP-2 in CRC cells lacking L1-enhanced cell proliferation (in the absence of serum), cell motility, tumorigenesis and induced liver metastasis, similar to L1 overexpression. Suppression of endogenous IGFBP-2 in L1-transfected cells inhibited these properties conferred by L1. We detected IGFBP-2 in a unique organization at the bottom of human colonic crypts in normal mucosa and at increased levels throughout human CRC tissue samples co-localizing with the phosphorylated p65 subunit of NF-κB. Finally, we found that IGFBP-2 and L1 can form a molecular complex suggesting that L1-mediated signaling by the L1–ezrin–NF-κB pathway, that induces IGFBP-2 expression, has an important role in CRC progression.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Similar content being viewed by others

References

  1. Clevers H . Wnt/β-catenin signaling in development and disease. Cell 2006; 127: 469–480.

    Article  CAS  Google Scholar 

  2. Polakis P . The many ways of Wnt in cancer. Curr Opin Genet Dev 2007; 17: 45–51.

    Article  CAS  Google Scholar 

  3. Brümmendorf T, Kenwrick S, Rathjen FG . Neural cell recognition molecule L1: from cell biology to human hereditary brain malformations. Curr Opin Neurobiol 1998; 8: 87–97.

    Article  Google Scholar 

  4. Hortsch M . Structural and functional evolution of the L1 family: are four adhesion molecules better than one? Mol Cell Neurosci 2000; 15: 1–10.

    Article  CAS  Google Scholar 

  5. Gavert N, Ben-Shmuel A, Raveh S, Ben-Ze’ev A . L1-CAM in cancerous tissues. Exp Opin Biol Ther 2008; 8: 1749–1757.

    Article  CAS  Google Scholar 

  6. Conacci-Sorrell M, Ben-Yedidia T, Shtutman M, Feinstein E, Einat P, Ben-Ze’ev A . Nr-CAM is a target gene of the β-catenin/LEF-1 pathway in melanoma and colon cancer and its expression enhances motility and confers tumorigenesis. Genes Dev 2002; 16: 2058–2072.

    Article  CAS  Google Scholar 

  7. Gavert N, Conacci-Sorrell M, Gast D, Schneider A, Altevogt P, Brabletz T et al. L1, a novel target of β-catenin signaling, transforms cells and is expressed at the invasive front of colon cancers. J Cell Biol 2005; 168: 633–642.

    Article  CAS  Google Scholar 

  8. Gavert N, Sheffer M, Raveh S, Spaderna S, Shtutman M, Brabletz T et al. Expression of L1-CAM and ADAM10 in human colon cancer cells induces metastasis. Cancer Res 2007; 67: 7703–7712.

    Article  CAS  Google Scholar 

  9. Gavert N, Ben-Shmuel A, Lemmon V, Brabletz T, Ben-Ze’ev A . Nuclear factor-κB signaling and ezrin are essential for L1-mediated metastasis of colon cancer cells. J Cell Sci 2010; 15: 2135–2143.

    Article  Google Scholar 

  10. Bretscher A, Edwards K, Fehon RG . ERM proteins and merlin: integrators at the cell cortex. Nat Rev Mol Cell Biol 2002; 3: 586–599.

    Article  CAS  Google Scholar 

  11. Fiévet B, Louvard D, Arpin M . ERM proteins in epithelial cell organization and functions. Biochim Biophys Acta 2007; 1773: 653–660.

    Article  Google Scholar 

  12. Gavert N, Vivanti A, Hazin J, Brabletz T, Ben-Ze’ev A . L1-mediated colon cancer cell metastasis does not require changes in EMT and cancer stem cell markers. Mol Cancer Res 2011; 9: 14–24.

    Article  CAS  Google Scholar 

  13. Gautreau A, Louvard D, Arpin M . Morphogenic effects of ezrin require a phosphorylation-induced transition from oligomers to monomers at the plasma membrane. J Cell Biol 2002; 10: 193–203.

    Google Scholar 

  14. Matsui T, Maeda M, Doi Y, Yonemura S, Amano M, Kaibuchi K et al. Rho-kinase phosphorylates COOH-terminal threonines of ezrin/radixin/moesin (ERM) proteins and regulates their head-to-tail association. J Cell Biol 1998; 140: 647–657.

    Article  CAS  Google Scholar 

  15. Ren L, Hong SH, Cassavaugh J, Osborne T, Chou AJ, Kim SY et al. The actin-cytoskeleton linker protein ezrin is regulated during osteosarcoma metastasis by PKC. Oncogene 2009; 28: 792–802.

    Article  CAS  Google Scholar 

  16. Mishra L, Bass B, Ooi BS, Sidawy A, Korman L . Role of insulin-like growth factor-I (IGF-I) receptor, IGF-I, and IGF binding protein-2 in human colorectal cancers. Growth Horm IGF Res 1998; 8: 473–479.

    Article  CAS  Google Scholar 

  17. Pollak M . Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008; 8: 915–928.

    Article  CAS  Google Scholar 

  18. Bulut G, Hong SH, Chen K, Beauchamp EM, Rahim S, Kosturko GW et al. Small molecule inhibitors of ezrin inhibit the invasive phenotype of osteosarcoma cells. Oncogene 2012; 19: 269–281.

    Article  Google Scholar 

  19. Tang F, Wang D, Duan C, Huang D, Wu Y, Chen Y et al. Berberine inhibits metastasis of nasopharyngeal carcinoma 5-8F cells by targeting Rho kinase-mediated Ezrin phosphorylation at threonine 567. J Biol Chem 2009; 284: 27456–27466.

    Article  CAS  Google Scholar 

  20. Firth SM, Baxter RC . Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 2002; 23: 824–854.

    Article  CAS  Google Scholar 

  21. Schütt BS, Langkamp M, Rauschnabel U, Ranke MB, Elmlinger MW . Integrin-mediated action of insulin-like growth factor binding protein-2 in tumor cells. J Mol Endocrinol 2004; 32: 859–868.

    Article  Google Scholar 

  22. Wang GK, Hu L, Fuller GN, Zhang W . An interaction between insulin-like growth factor-binding protein 2 (IGFBP2) and integrin α5 is essential for IGFBP2-induced cell mobility. J Biol Chem 2006; 281: 14085–14091.

    Article  CAS  Google Scholar 

  23. Mendes KN, Wang GK, Fuller GN, Zhang W . JNK mediates insulin-like growth factor binding protein 2/integrin α5-dependent glioma cell migration. Int J Oncol 2010; 37: 143–153.

    CAS  PubMed  Google Scholar 

  24. Miyako K, Cobb LJ, Francis M, Huang A, Peng B, Pintar JE et al. PAPA-1 is a nuclear binding partner of IGFBP-2 and modulates its growth-promoting actions. Mol Endocrinol 2009; 23: 169–175.

    Article  CAS  Google Scholar 

  25. Busund LT, Ow KT, Russell P, Crowe PJ, Yang JL . Expression of insulin-like growth factor mitogenic signals in adult soft-tissue sarcomas: significant correlation with malignant potential. Virchows Arch 2004; 444: 142–148.

    Article  CAS  Google Scholar 

  26. Cohen P, Peehl DM, Stamey TA, Wilson KF, Clemmons DR, Rosenfeld RG . Elevated levels of insulin-like growth factor-binding protein-2 in the serum of prostate cancer patients. J Clin Endocrinol Metab 1993; 76: 1031–1035.

    CAS  PubMed  Google Scholar 

  27. Elmlinger MW, Deininger MH, Schuett BS, Meyermann R, Duffner F, Grote EH et al. In vivo expression of insulin-like growth factor-binding protein-2 in human gliomas increases with the tumor grade. Endocrinology 2001; 142: 1652–1658.

    Article  CAS  Google Scholar 

  28. Hoeflich A, Reisinger R, Lahm H, Kiess W, Blum WF, Kolb HJ et al. Insulin-like growth factor-binding protein 2 in tumorigenesis: protector or promoter? Cancer Res 2001; 61: 8601–8610.

    CAS  Google Scholar 

  29. Karasik A, Menczer J, Pariente C, Kanety H . Insulin-like growth factor-I (IGF-I) and IGF-binding protein-2 are increased in cyst fluids of epithelial ovarian cancer. J Clin Endocrinol Metab 1994; 78: 271–276.

    CAS  PubMed  Google Scholar 

  30. El Atiq F, Garrouste F, Remacle BM, Sastre B, Pommier G . Alterations in serum levels of insulin-like growth factors and insulin-like growth-factor-binding proteins in patients with colorectal cancer. Int J Cancer 1994; 57: 491–497.

    Article  CAS  Google Scholar 

  31. Kaaks R, Toniolo P, Akhmedkhanov A, Lukanova A, Biessy C, Dechaud H et al. Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women. J Natl Cancer Inst 2000; 92: 1592–1600.

    Article  CAS  Google Scholar 

  32. Liou JM, Shun CT, Liang JT, Chiu HM, Chen MJ, Chen CC et al. Plasma insulin-like growth factor-binding protein-2 levels as diagnostic and prognostic biomarker of colorectal cancer. J Clin Endocrinol Metab 2010; 95: 1717–1725.

    Article  CAS  Google Scholar 

  33. Renehan AG, Painter JE, O’Halloran D, Atkin WS, Potten CS, O’Dwyer ST et al. Circulating insulin-like growth factor II and colorectal adenomas. J Clin Endocrinol Metab 2000; 85: 3402–3408.

    CAS  PubMed  Google Scholar 

  34. Png KJ, Halberg N, Yoshida M, Tavazoie SF . A microRNA regulon that mediates endothelial recruitment and metastasis by cancer cells. Nature 2011; 481: 190–194.

    Article  Google Scholar 

  35. Moore LM, Holmes KM, Smith SM, Wu Y, Tchougounova E, Uhrbom L et al. IGFBP2 is a candidate biomarker for Ink4a-Arf status and a therapeutic target for high-grade gliomas. Proc Natl Acad Sci USA 2009; 106: 16675–16679.

    Article  CAS  Google Scholar 

  36. Pollak M . The insulin receptor/insulin-like growth factor receptor family as a therapeutic target in oncology. Clin Cancer Res 2012; 18: 40–50.

    Article  CAS  Google Scholar 

  37. So AI, Levitt RJ, Eigl B, Fazli L, Muramaki M, Leung S et al. Insulin-like growth factor binding protein-2 is a novel therapeutic target associated with breast cancer. Clin Cancer Res 2008; 14: 6944–6954.

    Article  CAS  Google Scholar 

  38. Hlavin ML, Lemmon V . Molecular structure and functional testing of human L1CAM: an interspecies comparison. Genomics 1991; 11: 416–423.

    Article  CAS  Google Scholar 

  39. Degenhardt T, Matilainen M, Herzig KH, Dunlop TW, Carlberg C . The insulin-like growth factor-binding protein 1 gene is a primary target of peroxisome proliferator-activated receptors. J Biol Chem 2006; 281: 39607–39619.

    Article  CAS  Google Scholar 

  40. Langsrud Ø, Jørgensen K, Ragni Ofstad R, Næs T . Analyzing designed experiments with multiple responses. J Appl Stat 2007; 34: 1275–1296.

    Article  Google Scholar 

Download references

Acknowledgements

We thank Drs M Arpin, M Pollak, W Zhang and V Lemmon for providing reagents. This study was supported by grants from the Israel Science Foundation (ISF) and from Israel Cancer Research Fund (ICRF). AB-Z is the incumbent of the Lunenfeld-Kunin Professorial chair of genetics.

Author information

Authors and Affiliations

  1. Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel

    A Ben-Shmuel, A Shvab, N Gavert & A Ben-Ze'ev

  2. Department of Visceral Surgery, University of Freiburg, Freiburg, Germany

    T Brabletz

Authors
  1. A Ben-Shmuel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A Shvab
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. N Gavert
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T Brabletz
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A Ben-Ze'ev
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A Ben-Ze'ev.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ben-Shmuel, A., Shvab, A., Gavert, N. et al. Global analysis of L1-transcriptomes identified IGFBP-2 as a target of ezrin and NF-κB signaling that promotes colon cancer progression. Oncogene 32, 3220–3230 (2013). https://doi.org/10.1038/onc.2012.340

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/onc.2012.340

Keywords

This article is cited by

Search

Advanced search

Quick links